"Allogene Shifts Gears with New Strategy and Partnerships in Cell Therapy for Blood Cancer Amid Workforce Reduction"
TL;DR Summary
Allogene Therapeutics is altering its development strategy for ALLO-501A, an off-the-shelf cell therapy for blood cancer, due to intense competition from personalized CAR-T treatments. The company is discontinuing two ongoing clinical trials for patients with advanced-stage lymphoma and instead will initiate a new study targeting newly diagnosed high-risk lymphoma patients. This shift aims to position ALLO-501A more effectively in the competitive blood cancer treatment landscape.
Topics:business##allogenetherapeutics#bloodcancer#car-t#celltherapy#clinicaltrials#health-and-medicine
- Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer STAT
- Allogene makes 'bold' pivot, stopping pivotal trials in pursuit of first-line CAR-T cures FierceBiotech
- Allogene to cut 22% of its workforce Reuters.com
- Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma Yahoo Finance
- Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi STAT
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
40%
108 → 65 words
Want the full story? Read the original article
Read on STAT